CMRX - Chimerix, Inc.
| Previous Close | 2.6800 |
| Open | 2.6800 |
| Bid | 2.7000 x 800 |
| Ask | 2.7100 x 1800 |
| Day's Range | 2.6300 - 2.7300 |
| 52 Week Range | 1.7400 - 5.1000 |
| Volume | 186,254 |
| Avg. Volume | 540,254 |
| Market Cap | 138.457M |
| Beta (3Y Monthly) | 0.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4300 |
| Earnings Date | May 6, 2019 - May 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.80 |
- Simply Wall St.•11 days ago
One Thing To Remember About The Chimerix, Inc. (NASDAQ:CMRX) Share Price
If you own shares in Chimerix, Inc. (NASDAQ:CMRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatili...
- American City Business Journals•14 days ago
Chimerix taps former Endocyte executive as new CEO
Following the sudden departure of its last CEO earlier this year, Chimerix has tapped a pair of Endocyte executives to lead the company.
- Benzinga•14 days ago
The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 8) Alector Inc (NASDAQ: ALEC ) Denali Therapeutics Inc ...
- GlobeNewswire•15 days ago
Chimerix Announces Management Updates
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announces the appointment of Michael A. Sherman, former Chief Executive Officer of Endocyte, Inc., as Chief Executive Officer of Chimerix, effective immediately.
- American City Business Journals•18 days ago
Again, Durham pharma loses a drug development partner
One of Chimerix's development and commercial partners is out, disclosing this week it would be terminating a four-year-old licensing agreement after deciding to drop Chimerix's drug – the second time in less than five years the drug has been abandoned.
- Thomson Reuters StreetEvents•28 days ago
Edited Transcript of CMRX earnings conference call or presentation 5-Mar-19 1:30pm GMT
Q4 2018 Chimerix Inc Earnings Call
- Simply Wall St.•2 months ago
Should You Be Worried About Insider Transactions At Chimerix, Inc. (NASDAQ:CMRX)?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
- GlobeNewswire•2 months ago
Chimerix Announces Fourth Quarter and Full Year 2018 Financial Results
– Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30.
- GlobeNewswire•2 months ago
Chimerix to Present at Cowen and Company 39th Annual Health Care Conference
DURHAM, N.C., March 04, 2019 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced.
- GlobeNewswire•2 months ago
Chimerix to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019
DURHAM, N.C., Feb. 26, 2019 -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today.
- GlobeNewswire•2 months ago
Chimerix Presents Results from Post-hoc Analysis of Phase 3 Study
Decreased HHV-6 Reactivation Observed Among Oral Brincidofovir Allogeneic Hematopoietic Cell Transplantation Recipients Results to be Presented at Transplantation and Cellular.
- American City Business Journals•2 months ago
Chimerix filing reveals ex-CEO's severance package after sudden resignation
Following former Chimerix CEO Michelle Berrey’s sudden resignation, the company has detailed her severance package this week in an SEC filing.
- GlobeNewswire•2 months ago
New Research Coverage Highlights United Parcel Service, Healthcare Trust of America, CommVault, SPX FLOW, Chimerix, and International Speedway — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- American City Business Journals•2 months ago
Sudden Departure: Chimerix CEO, board member resigns
To fill the hole left by the sudden resignation of Michelle Berrey as the president and CEO of Chimerix, its board has appointed three company executives to serve in the interim capacity.
- GlobeNewswire•2 months ago
Chimerix Announces Management Transition
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey, M.D., M.P.H., has resigned from her role as Chimerix President and Chief Executive Officer. W. Garrett Nichols, Timothy W. Trost and Michael A. Alrutz have been appointed as members of a newly created position, the Office of the Chief Executive Officer, on an interim basis until a replacement is found.
- Simply Wall St.•3 months ago
What Type Of Shareholder Owns Chimerix, Inc.’s (NASDAQ:CMRX)?
Every investor in Chimerix, Inc. (NASDAQ:CMRX) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease Read More...
- Zacks•3 months ago
Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?
Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.
- Zacks•3 months ago
Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?
Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.
- Zacks•3 months ago
What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.
- Zacks•3 months ago
4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.
- GlobeNewswire•4 months ago
Chimerix to Present at the 37th Annual J.P. Morgan Healthcare Conference
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 10:00 a.m. PT (1:00 p.m. ET) at the Westin Saint Francis Hotel in San Francisco, CA. Dr. Berrey will present a corporate overview with plans and expected milestones for 2019, which will highlight the Company's core focus on progressing both oral, short-course brincidofovir (BCV) and the intravenous (IV) BCV program. Following planned discussions with FDA, the Company intends to progress IV BCV into a proof-of-concept study for the treatment of BK virus in kidney transplant recipients, while completing the phase 2 studies initiated during 2018 of IV BCV in adult stem cell transplant recipients with adenovirus infection.
- Insider Monkey•4 months ago
Should You Avoid Chimerix Inc (CMRX)?
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in October, blaming macroeconomic conditions and unpredictable events that hit several sectors, with healthcare among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent declines. […]
- Zacks•4 months ago
5 Beaten-Down Medical Product Stocks to Rebound in 2019
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
- Simply Wall St.•4 months ago
Is Chimerix, Inc. (NASDAQ:CMRX) Overpaying Its CEO?
M. Berrey became the CEO of Chimerix, Inc. (NASDAQ:CMRX) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we Read More...
